Cumberland Posts $77.8M Q3 Profit, Confirms Rolling NDA for DMD Cardiomyopathy
CPIX has more than doubled off its 52-week low of $1.85 on elevated volume (1.9× avg).
Summary
Cumberland's first full quarter as a pure development company produced $77.8 million of net income on revenue of $206,356, almost entirely the $81.1 million gain on the Apotex asset sale, while continuing operations lost $1.1 million. The balance sheet is the real story: $80.6 million in cash at September 30 against $42 million of liabilities, after paying the $22.5 million special dividend and clearing the revolver. Management confirmed it will file a rolling NDA for ifetroban in DMD cardiomyopathy, following a pre-NDA meeting this fall and FDA's grant of rolling review; the package rests on the Phase 2 FIGHT DMD trial's 5.4 percentage point improvement in left ventricular ejection fraction (p=0.002) plus natural-history controls and a 1,400-subject safety database. The Phase 2a ASSIST-SSc readout was a safety pass with no drug-related serious adverse events, but no efficacy claim was made — Cumberland will send the study report to FDA and run biomarker and cardiac imaging work before deciding on further SSc development. With no approved therapy for DMD heart disease and Orphan Drug, Rare Pediatric Disease and Fast Track designations in hand, the NDA submission timeline is the single variable that matters from here.
At the time of this announcement, CPIX was trading at $5.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.4M. The 52-week trading range was $1.85 to $9.28. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.